AU689642B2 - Steroids with a 17-spiromethylene lactone or lactol group - Google Patents

Steroids with a 17-spiromethylene lactone or lactol group Download PDF

Info

Publication number
AU689642B2
AU689642B2 AU34457/95A AU3445795A AU689642B2 AU 689642 B2 AU689642 B2 AU 689642B2 AU 34457/95 A AU34457/95 A AU 34457/95A AU 3445795 A AU3445795 A AU 3445795A AU 689642 B2 AU689642 B2 AU 689642B2
Authority
AU
Australia
Prior art keywords
hydroxy
lactone
alkyl
group
steroid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU34457/95A
Other languages
English (en)
Other versions
AU3445795A (en
Inventor
Johannes Antonius Maria Hamersma
Jaap Van Der Louw
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Akzo Nobel NV
Original Assignee
Akzo Nobel NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo Nobel NV filed Critical Akzo Nobel NV
Publication of AU3445795A publication Critical patent/AU3445795A/en
Application granted granted Critical
Publication of AU689642B2 publication Critical patent/AU689642B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J19/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 by a lactone ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J21/005—Ketals
    • C07J21/006—Ketals at position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0081—Substituted in position 17 alfa and 17 beta
    • C07J1/0088—Substituted in position 17 alfa and 17 beta the substituent in position 17 alfa being an unsaturated hydrocarbon group
    • C07J1/0092—Alkenyl derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J21/001—Lactones
    • C07J21/003—Lactones at position 17
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
    • C07J41/0016—Oximes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gynecology & Obstetrics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU34457/95A 1994-10-27 1995-10-25 Steroids with a 17-spiromethylene lactone or lactol group Ceased AU689642B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP94203117 1994-10-27
EP94203117 1994-10-27

Publications (2)

Publication Number Publication Date
AU3445795A AU3445795A (en) 1996-05-09
AU689642B2 true AU689642B2 (en) 1998-04-02

Family

ID=8217314

Family Applications (1)

Application Number Title Priority Date Filing Date
AU34457/95A Ceased AU689642B2 (en) 1994-10-27 1995-10-25 Steroids with a 17-spiromethylene lactone or lactol group

Country Status (26)

Country Link
US (1) US5741786A (https=)
EP (1) EP0709394B1 (https=)
JP (1) JPH08225590A (https=)
KR (1) KR100402636B1 (https=)
CN (1) CN1052237C (https=)
AT (1) ATE199015T1 (https=)
AU (1) AU689642B2 (https=)
BR (1) BR9504576A (https=)
CA (1) CA2161490A1 (https=)
CZ (1) CZ287346B6 (https=)
DE (1) DE69520022T2 (https=)
DK (1) DK0709394T3 (https=)
ES (1) ES2157290T3 (https=)
FI (1) FI113542B (https=)
GR (1) GR3035713T3 (https=)
HU (1) HU221192B1 (https=)
IL (1) IL115659A (https=)
NO (1) NO305252B1 (https=)
NZ (1) NZ280325A (https=)
PL (1) PL187083B1 (https=)
PT (1) PT709394E (https=)
RU (1) RU2168516C2 (https=)
SG (1) SG33569A1 (https=)
TR (1) TR199501327A2 (https=)
TW (1) TW339337B (https=)
ZA (1) ZA958963B (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6407082B1 (en) * 1996-09-13 2002-06-18 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of a vitamin D compound
US6511970B1 (en) 1996-09-13 2003-01-28 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of products that induce transforming growth factor-beta and/or apoptosis in the ovarian epithelium
US6034074A (en) 1996-09-13 2000-03-07 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of a Vitamin D compound
US6028064A (en) 1996-09-13 2000-02-22 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of progestin products
US6765002B2 (en) 2000-03-21 2004-07-20 Gustavo Rodriguez Prevention of ovarian cancer by administration of products that induce transforming growth factor-β and/or apoptosis in the ovarian epithelium
DE19651000A1 (de) * 1996-12-01 1998-06-04 Schering Ag Oxyiminopregnancarbolactone
AU4093799A (en) 1998-05-22 1999-12-13 Board Of Trustees Of The Leland Stanford Junior University Bifunctional molecules and therapies based thereon
US6043235A (en) * 1999-07-21 2000-03-28 Research Triangle Institute 11β-aryl-17, 17-spirothiolane-substituted steroids
US20010044431A1 (en) * 2000-03-21 2001-11-22 Rodriguez Gustavo C. Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium
AU2002322720B2 (en) 2001-07-25 2008-11-13 Raptor Pharmaceutical Inc. Compositions and methods for modulating blood-brain barrier transport
CA2789262C (en) 2005-04-28 2016-10-04 Proteus Digital Health, Inc. Pharma-informatics system
EP1945240B1 (en) 2005-09-16 2016-12-28 Raptor Pharmaceutical Inc Compositions comprising receptor-associated protein (rap) variants specific for cr-containing proteins and uses thereof
TR201908314T4 (tr) 2009-02-20 2019-06-21 2 Bbb Medicines B V Glutatyon bazlı ilaç dağıtım sistemi.
KR101909711B1 (ko) 2009-05-06 2018-12-19 라보라토리 스킨 케어, 인크. 활성제-칼슘 포스페이트 입자 복합체를 포함하는 피부 전달 조성물 및 이들을 이용하는 방법
WO2021198467A1 (en) * 2020-04-03 2021-10-07 Rockwool International A/S Method of draining water

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3764596A (en) * 1971-06-22 1973-10-09 Sandoz Ag 17-dihydrofuranyl-substituted steroids
EP0558416A1 (fr) * 1992-02-27 1993-09-01 Roussel Uclaf Nouveaux stéroides comportant en position 17 un radical méthylène lactone, leur procédé et des intermédiaires de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2875199A (en) * 1958-04-22 1959-02-24 Searle & Co Lactones of 17-carboxyalkylated estra-1, 3, 5(10)-triene-3, 17-diols and 3-ethers
US3547912A (en) * 1968-07-29 1970-12-15 American Home Prod Derivatives of 2h-pyran-3(6h)-ones and preparation thereof
DE3306554A1 (de) * 1983-02-22 1984-08-23 Schering AG, 1000 Berlin und 4709 Bergkamen Verfahren zur herstellung von 3-((delta)(pfeil hoch)4(pfeil hoch)-3-ketosteroid-17(alpha)-yl)-propionsaeurelactonen
DE3347510A1 (de) * 1983-12-27 1985-08-01 Schering AG, 1000 Berlin und 4709 Bergkamen Verfahren zur herstellung von 3-oxo-17(alpha)-pregna-4,6-dien-21,17-carbolactonen
FR2596395B1 (fr) * 1986-03-26 1989-05-26 Roussel Uclaf Nouveaux steroides comportant un cycle spirannique en position 17, leur procede de preparation, leur application comme medicaments et les compositions les renfermant
ES2053714T3 (es) * 1987-12-12 1994-08-01 Akzo Nv Proceso para la preparacion de 11-arilesteroides.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3764596A (en) * 1971-06-22 1973-10-09 Sandoz Ag 17-dihydrofuranyl-substituted steroids
EP0558416A1 (fr) * 1992-02-27 1993-09-01 Roussel Uclaf Nouveaux stéroides comportant en position 17 un radical méthylène lactone, leur procédé et des intermédiaires de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant

Also Published As

Publication number Publication date
PT709394E (pt) 2001-06-29
CA2161490A1 (en) 1996-04-28
NO305252B1 (no) 1999-04-26
ATE199015T1 (de) 2001-02-15
GR3035713T3 (en) 2001-07-31
EP0709394B1 (en) 2001-01-31
KR100402636B1 (ko) 2004-02-05
IL115659A (en) 2000-06-01
HU221192B1 (en) 2002-08-28
DE69520022D1 (de) 2001-03-08
PL187083B1 (pl) 2004-05-31
RU2168516C2 (ru) 2001-06-10
KR960014152A (ko) 1996-05-22
FI955108L (fi) 1996-04-28
SG33569A1 (en) 1996-10-18
EP0709394A2 (en) 1996-05-01
ZA958963B (en) 1996-05-23
NO954293D0 (no) 1995-10-26
IL115659A0 (en) 1996-01-19
PL311135A1 (en) 1996-04-29
DE69520022T2 (de) 2001-06-13
NZ280325A (en) 1997-03-24
EP0709394A3 (en) 1996-09-18
AU3445795A (en) 1996-05-09
TR199501327A3 (https=) 1996-06-21
BR9504576A (pt) 1997-05-20
US5741786A (en) 1998-04-21
CN1131158A (zh) 1996-09-18
TR199501327A2 (tr) 1996-06-21
FI955108A0 (fi) 1995-10-26
HU9503068D0 (en) 1995-12-28
HUT73482A (en) 1996-08-28
CZ275595A3 (en) 1996-05-15
JPH08225590A (ja) 1996-09-03
FI113542B (fi) 2004-05-14
DK0709394T3 (da) 2001-06-18
ES2157290T3 (es) 2001-08-16
CZ287346B6 (en) 2000-10-11
CN1052237C (zh) 2000-05-10
TW339337B (en) 1998-09-01
NO954293L (no) 1996-04-29

Similar Documents

Publication Publication Date Title
AU689642B2 (en) Steroids with a 17-spiromethylene lactone or lactol group
US5292878A (en) 17-spirofuran-3'-ylidene steroids
DE69326805T2 (de) 17-Spiromethylensteroide
DE3625315A1 (de) 11ss-(4-isopropenylphenyl)-estra-4,9-diene, deren herstellung und diese enthaltende pharmazeutische praeparate
EP1237904B1 (en) 14,15-beta-methylene substituted androgens
KR100341066B1 (ko) 게스타겐활성의19,11-다리결합4-에스트렌
US5827842A (en) 14α, 17α-C2 -bridged norprogesterone derivatives
KR100730010B1 (ko) 신규 안드로겐
HK1002033B (en) 17-spirofuran-3'-ylidene steroids
WO1995027725A1 (de) 11β,19-ÜBERBRÜCKTE 13α-ALKYLSTEROIDE
WO1995011915A1 (de) 10,11β-C2-ÜBERBRÜCKTE STEROIDE
DE19535851A1 (de) 18-Norsteroide mit gestagener Wirkung